A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Conditions
- Agitation Associated With
- Alzheimer's Disease
- Alzheimer's Type
- Mental Disorder
- Nervous System Diseases
Interventions
- DRUG: Brexpiprazole, OPC-34712
- DRUG: Placebo Oral Tablet
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators